Vanguard Group Inc Verve Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding VERV
# of Institutions
170Shares Held
78.3MCall Options Held
125KPut Options Held
185K-
Alphabet Inc. Mountain View, CA12.3MShares$61.7 Million7.28% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.04MShares$30.2 Million0.57% of portfolio
-
Black Rock Inc. New York, NY5.37MShares$26.9 Million0.0% of portfolio
-
State Street Corp Boston, MA5.1MShares$25.5 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.58MShares$22.9 Million0.04% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $300M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...